Estimating the burden of post-COVID-19 syndrome in a population-based cohort study of SARS-CoV-2 infected individuals: Implications for healthcare service planning

Dominik Menges[1] *, Tala Ballouz[1] *, Alexia Anagnostopoulos[1], Hélène E Aschmann[1], Anja Domenghino[1,2], Jan S Fehr[1,3], Milo A Puhan[1]

[1] *Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland*
[2] *Department of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich, University of Zurich, Switzerland*
[3] *Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland*

* These authors contributed equally to this work.

Corresponding author:
Milo A Puhan
Epidemiology, Biostatistics and Prevention Institute
University of Zurich, Zurich, Switzerland
Telephone: +41 44 634 46 10
Email: miloalan.puhan@uzh.ch

Abstract

Objective To assess the prevalence of impaired health status and physical and mental health symptoms among individuals at least six months after SARS-CoV-2 infection, and to characterise their healthcare utilisation.
Design Population-based prospective cohort study.
Setting Zurich SARS-CoV-2 Cohort, Zurich, Switzerland.
Participants 431 adults from the general population with PCR-confirmed SARS-CoV-2 infection reported to health authorities between 27 February 2020 and 05 August 2020.
Main outcome measures We assessed the proportion of individuals reporting not having fully recovered since SARS-CoV-2 infection, the proportion reporting fatigue (assessed by Fatigue Assessment Scale), dyspnoea (assessed by mMRC dyspnoea scale) or depression (assessed by DASS-21) at six to eight months after diagnosis. We further evaluated the proportion of individuals with at least one healthcare contact since their acute illness. Multivariable logistic regression models were used to assess factors associated with the main outcomes.
Results Symptoms were present in 385 (89%) participants at diagnosis and 81 (19%) were initially hospitalised. At six to eight months, 111 (26%) reported not having fully recovered. 233 (55%) participants reported symptoms of fatigue, 96 (25%) had at least grade 1 dyspnoea, and 111 (26%) had DASS-21 scores indicating symptoms of depression. 170 (40%) participants reported at least one general practitioner visit related to COVID-19 after acute illness, and 10% (8/81) of initially hospitalised individuals were rehospitalised. Individuals that have not fully recovered or suffer from fatigue, dyspnoea or depression were more likely to have further healthcare contacts. However, a third of individuals (37/111) that have not fully recovered did not seek further care.
Conclusion In our population-based study, a relevant proportion of individuals suffered from longer-term consequences after SARS-CoV-2 infection. Our findings indicate that a considerable number of individuals affected by post-COVID-19 syndrome is to be expected, and that a wide range of additional healthcare services and integrative approaches will be required to support the recovery of these individuals. Thus, the timely planning of resources and services for post-COVID-19 care will be necessary alongside public health measures to mitigate the effects of the pandemic.
Registration ISRCTN14990068

Background

As of February 2021, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in more than 110 million infected cases and almost 2.5 million lives lost, at significant costs to healthcare systems and societies worldwide.[1] As the pandemic expanded, initial efforts focused on characterising the epidemiological and clinical features of coronavirus disease 2019 (COVID-19), and public health measures primarily aimed at reducing transmission and limiting the acute burden on healthcare systems. Today, a growing body of evidence indicates that COVID-19 can also result in longer-term consequences, the implications of which are an increasing public health concern.[2–4]

Several observational studies of mostly patients with prior hospital admission due to COVID-19 have examined the persistence of symptoms and development of complications.[5–8] A recent study suggested that up to 76% of these individuals may experience a wide range of persistent complaints, such as fatigue, dyspnoea, cough, and smell and taste disturbances, for at least six months after the initial infection.[5] In combination with the general psychological toll of the pandemic, persistent symptoms and resulting limitations in daily activities may have additionally intensified the risk of developing anxiety or depression. Other studies in hospitalised patients found that up to 20% of patients have to be rehospitalised,[7] and up to 80% may require further follow-up in primary care.[8] While not yet conclusively circumscribed, these longer-term physical and mental health consequences of COVID-19 lasting more than 12 weeks after infection are currently referred to as “post-COVID-19 syndrome”.[4] Current evidence shows that post-COVID-19 syndrome does not only occur in individuals with severe disease requiring hospitalisation or in older individuals with comorbidities, but also in young and previously healthy individuals with mild disease.[3,9–11] It is increasingly acknowledged that specific healthcare services and resources will be required to support the needs of individuals suffering from post-COVID-19 syndrome.[2,4,12] Meanwhile, the full burden of post-COVID-19 syndrome in the broader population of infected individuals is currently unclear.

In several countries, specialised care centres are being set up to ensure continuity of care during and after COVID-19. For instance, the National Health Service (NHS) in the United Kingdom has established a network of more than 60 specialised clinics offering multidisciplinary assessments and resources to patients suffering from longer-term consequences after infection.[13] In addition, the National Institute of Health and Care Excellence (NICE) recently published a guidance for healthcare professionals involved in the management and care for people suffering from post-COVID-19 syndrome.[4] In the United States, several clinics have been set up offering physical, psychiatric and occupational rehabilitation and care services that aim to address these individuals’ multi-systemic needs.[14] Moreover, a multitude of patient support groups and networks for individuals suffering from the syndrome have been formed, enabling a discussion among patients, their families and healthcare professionals to advocate for better understanding and care of post-COVID-19 syndrome.[12]

To successfully plan healthcare services and efficiently allocate public health resources, it is critical to determine the burden of longer-term consequences of SARS-CoV-2 infection and the

various needs of individuals suffering from post-COVID-19 syndrome. In this population-based study of SARS-CoV-2 infected individuals surveyed at least six months after diagnosis, we aimed to assess the longer-term physical and mental health impact of COVID-19, as well as the associated healthcare utilisation. Thereby, we aimed to provide an evidence base for the planning of healthcare services to care for individuals suffering from post-COVID-19 syndrome.

Methods

Study design and participants

We conducted this study using data from individuals with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection diagnosed between 27 February 2020 and 05 August 2020. Participants are part of the Zurich SARS-CoV-2 Cohort study, a prospective, longitudinal cohort of SARS-CoV-2 infected individuals in the Canton of Zurich, Switzerland. The cohort was established in collaboration with the Department of Health of the Canton of Zurich and aims to characterise clinical outcomes and immune responses of individuals testing positive for SARS-CoV-2 up to one year after diagnosis.

We recruited study participants from within contact tracing of the Department of Health, based on mandatory laboratory reporting of all individuals diagnosed with SARS-CoV-2. We screened all SARS-CoV-2 positive cases for whom contact information was available for eligibility (i.e., either a phone number or an email address was required). Eligibility criteria were being aged 18 years or older and able to follow study procedures, having sufficient knowledge of the German language, and residing in the Canton of Zurich. We enrolled participants into the study between 06 October 2020 and 26 January 2021, with a median of 7.2 months (range 5.9 to 10.3 months) after their diagnosis.

Data sources and measurement

After enrolment, participants completed an electronic baseline questionnaire which included questions on socio-demographics, medical comorbidities, smoking, as well as details on their acute SARS-CoV-2 infection, current health status, healthcare contacts and care trajectory since diagnosis, and health-related quality of life. All data was collected and managed through the Research Electronic Data Capture (REDCap) online survey system.

Features of acute COVID-19

We defined acute COVID-19 as signs and symptoms within four weeks of diagnosis. We elicited data on the presence, duration and self-perceived severity of symptoms (assessed using a 4-point scale; i.e., mild, moderate, severe, and very severe) at the time of infection. Furthermore, we collected information on hospitalisation and ICU admission.

Current health status at least six months after diagnosis

To capture the longer-term effects of SARS-CoV-2 infection, we evaluated recovery in terms of the relative health status of participants who were symptomatic in the acute phase compared to their normal health status before infection using a four-category scale (i.e., feeling “recovered and symptom free”, “better but not fully recovered”, “neither better nor worse”, or “worse").

Furthermore, we assessed the presence and type of any new or ongoing symptoms since the acute illness using a comprehensive list of symptoms and additional free text fields for symptoms not captured in the preconceived questionnaire.

We evaluated the presence of fatigue using the Fatigue Assessment Scale (FAS), a 10-item instrument assessing self-perceived presence of physical and mental fatigue. Participants were categorised according to official guidance, using a score of 22 or more as a threshold for determining the presence of fatigue.[15]

To assess longer-term respiratory complications, we administered the modified Medical Research Council (mMRC) dyspnoea scale. In this validated five-category assessment of self-perceived breathlessness in daily living, higher scores indicate a greater disability in performing daily life activities.[16]

We assessed the presence and severity of depression, anxiety and stress symptoms using the 21-item Depression, Anxiety and Stress Scale (DASS-21). The instrument measures negative emotional states experienced over the past week using a 4-point Likert-type scale. Scores were calculated as the sum of the responses to the seven items from each subscale multiplied by two. We assigned participant scores the corresponding degree of symptoms (i.e., none, mild, moderate, severe, and extremely severe) for each subscale, according to official user guidance.[17,18]

To evaluate health-related quality of life (HRQoL), we used the EQ-5D-5L instrument and the associated visual analogue scale (EQ VAS). The EQ-5D-5L assesses the dimensions of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. The level of problems in each dimension was measured on a five-point ordinal scale, ranging from no problems to complete inability or extreme symptoms. The EQ VAS measures participants' self-assessment of their current health status on a scale from 0 (worst health imaginable) to 100 (best health imaginable).[19,20] We used the value set from the Netherlands for calculating EQ-5D-5L index scores, as no value set or guidance on the most appropriate value set is available for Switzerland, and as we judged the population of the Netherlands to be relatively similar to the Swiss population.

Healthcare utilisation

We assessed utilisation of healthcare services by asking participants to report any healthcare contact that they have had since their acute illness. This included any general practitioner visits, medical hotline calls, and hospital admissions. We asked participants to provide the main reason for each contact (for a maximum of 5 contacts for each type of healthcare contact), particularly whether these were due to persistent or worsening of COVID-19 related symptoms, complication or new medical diagnoses related to COVID-19, routine monitoring or follow-up after COVID-19, or reasons unrelated to COVID-19. To capture healthcare utilisation specifically due to COVID-19, we restricted our analysis to healthcare contacts that were reported to be related to COVID-19. In addition, we asked participants to report on any medical conditions that have been newly diagnosed since their acute illness and whether the condition is related to COVID-19 as was determined by their physician.

Outcomes

Primary outcomes of this study were the proportion of individuals reporting not having fully recovered since the time of diagnosis, the proportion of participants with fatigue as determined by the FAS, the proportion of participants with at least grade 1 dyspnoea on the mMRC dyspnoea scale, the proportion of participants with symptoms of depression as determined by the DASS-21, and the proportion of participants that had at least one further healthcare contact since the acute illness.

Secondary outcomes included the proportion of individuals with new or ongoing symptoms, median number of healthcare contacts per participant (i.e., general practitioner visits, medical hotline calls and rehospitalisations related to COVID-19), the proportion of individuals with one or more new medical diagnoses related to COVID-19, the proportion of participants with symptoms of anxiety and stress as determined by the DASS-21, the proportion of individuals with at least slight problems in the five dimensions of the EQ-5D-5L, as well as EQ-5D-5L index and EQ VAS scores. Last, we also evaluated the social impact of the infection and isolation in terms of a change in the scope of work, financial difficulties due to changes in the scope of work, as well as a reduced income.

Statistical Analysis

We used descriptive statistics to analyse participant characteristics and outcomes of interest of this study. We report median and interquartile range (IQR) for continuous variables and frequency and percentage for categorical variables, as applicable. Responses regarding symptoms in free text fields were reviewed and coded to reflect the presence (or absence) of new or ongoing symptoms since the acute illness. We present results for primary and secondary outcomes stratified by age groups, sex, and hospitalisation status as well as in the overall study population.

We examined the data for missing values and report such where applicable. For responses to the FAS and DASS-21 instruments, we replaced missing data with the mean of the scores from the other available items. This was done for a maximum of two missing values for the FAS and for a maximum of one value for the DASS-21. We omitted FAS or DASS-21 responses with higher amounts of missing data from respective analyses. For the EQ-5D, responses with invalid and missing data were omitted given the small amount of missing data (n=4). No imputation was applied for other missing data.

In further analyses, we assessed the associations of potential predictors with the primary outcomes using uni- and multivariable logistic regression models. We based model selection on clinical and epidemiological reasoning, as well as the Akaike Information Criterion (AIC). We defined age group, sex and initial hospitalisation as a priori covariables in the models based on the findings of other studies. We performed model selection separately for each outcome of interest by including variables that improved model fit based on AIC, with a difference of 2 points considered relevant. For participants returning to normal health status, analysis was restricted to initially symptomatic participants since the respective question was conditional on the presence of symptoms at time of infection. We report results as odds ratios (OR) with corresponding 95%

confidence interval (CI) and two-sided Wald-type statistical test. No p-value adjustment was applied.

We conducted sensitivity analyses to assess changes in participant population and the responses with time. We stratified the results into time periods with limited testing (period before 25 June 2020, testing restricted to high-risk or severely symptomatic individuals) and increased testing (period after 25 June 2020, all symptomatic individuals could be tested). Furthermore, we stratified results into time periods with limited and high public awareness of post-COVID-19 syndrome (period before and after 09 November 2020, when major Swiss news outlets started reporting about the syndrome). Furthermore, we descriptively compared participants and nonparticipants for age, sex, presence of symptoms and hospitalisation at infection to assess potential selection of participants.

All analyses were performed using R version 4.0.2.

Patient and Public Involvement

Patients were not involved in the design and conduct of the cohort study, the development of the research questions and aims, or in the interpretation and writing up of the results. At the current stage of the pandemic, any patient and public involvement during the design and implementation of this research project would have been highly challenging and may have delayed its rapid implementation.

Results

Study population

Between 27 February 2020 and 05 August 2020, 4639 individuals were diagnosed with SARS-CoV-2 in the Canton of Zurich, Switzerland. Contact information was available for 2209 individuals. Among these, 1309 were eligible and invited to participate, and 442 individuals agreed to participate in our study (participation rate 34%). Five individuals never completed the baseline questionnaire and were excluded from analysis. Furthermore, we excluded six individuals who had a suspected reinfection (i.e., individuals with two laboratory reports of SARS-CoV-2 infection more than two months apart), to avoid that symptoms related to the second infection influenced our results (Figure 1).

The median age of participants was 47 years (IQR 33 - 58 years) and 214 (50%) were female. At least one chronic comorbid medical condition was reported by 147 (34%) participants, with the most common comorbidity being hypertension (n=79, 19%), followed by respiratory comorbidities (n=33, 8%) and cardiovascular disease (n=31, 8%). Participants filled the questionnaires at a median of 7 months (IQR 6 to 8 months) after their SARS-CoV-2 diagnosis. During the acute infection phase, 385 (89%) participants were symptomatic, with a median count of 6 (IQR 3 to 8) symptoms. Symptoms were described as mild to moderate in 221 (51%) participants and severe to very severe in 164 participants (38%). The most commonly reported symptoms were fatigue (n=274, 64%), fever (n=271, 63%), cough (n=214, 50%) and loss of taste or smell (n=211, 49%), and the median duration of symptoms was 10 days (IQR 6 to 20 days). One fifth (n=81, 19%) of

participants were hospitalised due to COVID-19 for a median duration of 7 days (IQR 4 to 15 days). Among those, ten were admitted to an intensive care unit (12% among those hospitalised and 2.3% among all participants), with seven (70%) requiring mechanical ventilation (Table 1).

Return to normal health status and symptoms

Overall, 111 (26%) participants reported that they had not fully recovered at six to eight months after SARS-CoV-2 infection. A higher percentage of female participants reported not having recovered compared to males (31% versus 21%). We observed a higher percentage of non-recovered participants among 40-64 year-olds compared to older and younger age groups (32% versus 24% in ≥65 year-olds and 19% in 18-39 year-olds). Furthermore, a higher percentage of initially hospitalised individuals reported not to have recovered compared to those that did not require hospitalisation (36% versus 23%) (Table 2). In multivariable analyses among initially symptomatic participants, we found evidence that severe to very severe symptoms during acute illness (OR 2.05, 95% CI 1.27 to 3.34, p=0.003) and the presence of comorbidities (OR 2.08, 95% CI 1.24 to 3.50, p=0.005) were associated with higher odds of not having recovered. In addition, females were less likely to have recovered at 6-8 months after diagnosis compared to males (OR 0.53, 95% CI 0.33 to 0.85, p=0.009) (Supplementary Material, Table S4).

Similarly, 106 (25%) participants reported to have ongoing or new symptoms, with a higher percentage in females compared to males (29% versus 20%). Fatigue (n=52, 12%), cough (n=41, 10%), sore throat (n=38, 9%) and headache (n=37, 9%) were the most frequently reported new or ongoing symptoms. Taste and smell disturbances were reported by 21 (5%) and rash by 3 (1%) individuals. Among participants who reported not having fully recovered, 51 (46%) also described ongoing symptoms. Meanwhile, 55 (52%) of participants reporting new or ongoing symptoms stated not have fully recovered. Overall, 166 (39%) of participants reported either not having fully recovered or having new or ongoing symptoms (Table 2).

Fatigue

Among all participants, the median FAS score was 22 (IQR 19 to 25), with 233 (55%) participants having a score indicating fatigue. Individuals aged 18-39 years more frequently reported symptoms of fatigue compared to older age groups (64% compared to 51% in 40-64 year-olds and 41% in ≥65 year-olds). Furthermore, female participants more often reported fatigue compared to males (59% versus 50%). Last, we also observed differences between those hospitalised for COVID-19 initially and those not requiring hospitalisation (56% versus 49%) (Table 2). In multivariable analyses, we found evidence that those aged 40-64 years (OR 0.59, 95% CI 0.39 to 0.91, p=0.018) and those aged ≥65 years (OR 0.41, 95% CI 0.21 to 0.78, p=0.007) were less likely to experience fatigue compared to individuals aged 18-39 years. We found no evidence for an association between sex, initial symptom severity, hospitalisation, ICU admission, smoking status or comorbidities and presence of fatigue after six to eight months (Supplementary Material, Table S5).

Dyspnoea

A total of 96 (25%) participants reported to suffer from dyspnoea to some extent (i.e., mMRC grade ≥1). 81 (21%) reported grade 1 dyspnoea and 15 (4%) stated to have grade 2 dyspnoea or

higher. We observed a higher percentage of grade ≥1 dyspnoea among older age individuals, females, and initially hospitalised participants (Table 2). In multivariable analyses, we found evidence for an association of grade ≥1 dyspnoea with female sex (OR 2.24, 95% CI 1.31 to 3.87, p=0.003), initial hospitalisation (OR 4.17, 95% CI 2.23 to 7.91, p<0.001) and body mass index (OR 1.14 per unit increase, 95% CI 1.08 to 1.20, p<0.001), but not with age, initial symptom severity, smoking or respiratory comorbidity (Supplementary Material, Table S6).

Depression, anxiety and stress

Based on the DASS-21, we found that 111 (26%) study participants reported symptoms of depression, 135 (32%) reported symptoms of anxiety, and 68 (16%) reported symptoms of stress. The proportion of participants reporting depressive symptoms was higher in older age groups and in females. Similar contrasts were observed for symptoms of anxiety. Meanwhile, younger participants and females more often reported stress symptoms compared to older individuals and males, respectively (Table 2). In multivariable analyses, we found no evidence for an association of depression with age, sex, initial hospitalisation, severity of symptoms at diagnosis, or the presence of comorbidities. However, lower education status and being unemployed were associated with higher odds of having depression symptoms (Supplementary Material, Table S7).

Health-related quality of life

Overall, 225 (53%) of participants reported problems in at least one dimension of the EQ-5D-5L. The most frequently affected dimensions were pain or discomfort (n=151, 39%) and anxiety or depression (n=133, 31%). In both dimensions, females were more commonly affected than males. Differences in age groups were also noted with higher levels of pain or discomfort in those aged ≥65 compared to younger age groups, while higher levels of anxiety or depression were observed in those aged 18-39 years compared to older age groups. Overall, participants reported health states translating to EQ-5D-5L index scores ranging from 0.07 to 1.00, with a median index score of 0.89 (IQR 0.85 to 1.00) and median EQ VAS score of 85 (IQR 77 to 90) (Table 2).

Overlap across main outcomes

Figure 2 demonstrates the overlap across the primary outcomes of non-recovery, fatigue, dyspnoea and depression among those experiencing at least one of the outcomes (n=296). All four outcomes were present in 19 (6.4%) participants. Most common combinations were fatigue and depression (n=94, 32%), fatigue and not having recovered (n=78, 26%), as well as fatigue and dyspnoea defined as mMRC grade ≥1 (n=68, 23%). Overall, 296 (69%) participants were categorised as having any of these four outcomes.

Healthcare services utilisation

A total of 170 (40%) participants reported having had at least one contact with the healthcare system (i.e., rehospitalisation, general practitioner visits, or medical hotline calls) for reasons related to COVID-19. Out of 81 individuals who were initially hospitalised due to COVID-19, eight (10%) were admitted to a hospital again at least once due to persistent symptoms or COVID-19 related complications, with a maximum of three rehospitalisations. More than half of the participants (n=224, 52%) reported at least one general practitioner visit for any reason, and 150 (36%) had a general practitioner visit related to COVID-19. Among those, the median number of

general practitioner visits related to COVID-19 was 2 (IQR 1 to 3). Older individuals (53% in those aged ≥65 years compared to 43% in 40-64 year-olds and 20% in 18-39 year-olds) and those initially hospitalised (63% versus 29% in non-hospitalised) more frequently reported to have seen their general practitioner. Furthermore, 31 (7%) participants reported to have called a medical hotline at least once for a reason related to COVID-19, with a median of 1 call (IQR 1 to 2) (Table 3). Among those that had not fully recovered, 37 (33%) did not report further healthcare contacts (Supplementary Material, Table S1).

Since SARS-CoV-2 infection, a new physician-diagnosed medical condition was reported by 77 (18%) participants. 27 (35%) of these diagnoses were considered to be related to COVID-19 by a physician. The most frequently reported medical conditions related to COVID-19 concerned the respiratory system (n=15, 56%), followed by neuro-cognitive (n=8, 30%), cardiovascular (n=3, 11%), and skin disorders (n=3, 11%). Eleven additional participants (14%) stated to have a complication which they self-evaluated to be related to COVID-19, which was not diagnosed as such by a physician. In multivariable regression analyses, we found evidence for an association between healthcare use and initial hospitalisation, having experienced severe to very severe symptoms, sex, and age ≥40 years. Furthermore, not having fully recovered (OR 3.53, 95% CI 2.14 to 5.86, p<0.001), experiencing grade ≥1 dyspnoea (OR 2.35, 95% CI 1.40 to 3.99, p<0.001), fatigue (OR 1.61, 95% CI 1.04 to 2.50, p=0.03) and symptoms of depression (OR 2.13, 95% CI 1.32 to 3.45, p=0.002) were independently associated with having contact with the healthcare system (Supplementary Material, Table S8).

Socio-economic consequences

When asked about the socio-economic consequences due to SARS-CoV-2 infection or isolation, 186 (44%) participants stated to have had temporary or permanent changes in the scope of work. Among those that incurred a change in the scope of work, 20 (11%) individuals reported to have financial difficulties due to the change in work conditions. Overall, 49 (12%) participants reported to have had a reduced income due to SARS-CoV-2 infection or isolation, which primarily affected the younger age groups (Table 3).

Discussion

Principal Findings

In this population-based cohort study, we found that one in four people did not recover to their normal health status within six to eight months after SARS-CoV-2 infection. More than half of the participants in our study reported symptoms of fatigue, and one fourth suffered from some degree of dyspnoea or had symptoms of depression. Overall, we found that more than two thirds had not recovered, or experienced fatigue, dyspnoea or depression at the time of follow-up. While we observed some overlap between these outcomes, a relevant proportion was only affected by one of them. While it needs to be noted that not all of these issues are necessarily attributable to COVID-19, our study showed that a large proportion of infected individuals may develop some form of post-COVID-19 syndrome and that a wide range of services may be required to support them in their daily lives.

When assessing healthcare service utilisation, we found that two fifths of study participants had at least one further contact with the healthcare system related to COVID-19. This included visits to a general practitioner and calls to a medical hotline by 36% and 7% of participants, respectively. Furthermore, we found that 10% of those who were hospitalised due to COVID-19 were rehospitalised at least once for persistent symptoms or complications after acute illness. Compared to those who had recovered, individuals who had not fully recovered were more than three times more likely to have at least one healthcare contact. Similarly, increased odds of having further healthcare contacts were observed in participants that were initially hospitalised, as well as those experiencing symptoms of fatigue, dyspnoea or depression. Taken together, these findings highlight the considerable long-term impact that COVID-19 may have not only on individuals but also on healthcare systems worldwide, as the number of individuals recovering from COVID-19 continues to increase.

Comparison with other studies

In the NICE guidelines, post-COVID-19 syndrome was defined as signs and symptoms that have developed during or after COVID-19 and continued for more than 12 weeks.[4] This is delimited from ongoing symptomatic COVID-19, defined as protracted symptoms lasting between 4 and 12 weeks after acute illness. According to this definition, most reports in the peer-reviewed literature to date have primarily characterised ongoing symptomatic COVID-19. Various studies have described a wide range of physical, cognitive and psychological symptoms persisting up to three months in individuals recovering from COVID-19.[21–30] Yet, only few studies have assessed the persistence of symptoms beyond three months of follow-up.[5,6,9]

The study by Huang et al. described the health consequences in more than 1700 individuals who were previously hospitalised with COVID-19 after six months.[5] The authors found that 76% of patients were experiencing one or more of a wide range of symptoms. Most frequently reported symptoms were fatigue and muscle weakness (63%), with longer-term symptoms occurring more often in those who were more severely ill. The symptom-related estimates from their study are relevantly higher than the ones we observed. While the differences could be partly due to the older participant population and the restriction to hospitalised patients in their study, we still observed lower proportions of non-recovery, as well as new and ongoing symptoms among hospitalised patients and older individuals. Another cohort of 238 patients who suffered from severe COVID-19 requiring hospitalisation also found a higher prevalence (50%) of persistent symptoms four months after hospital discharge compared to our study.[6] Logue et al. presented data from a longitudinal cohort of 177 infected individuals, which included 91% of participants with asymptomatic or mild disease.[9] They reported that 33% of outpatients and 31% of hospitalized patients reported persistent symptoms, with fatigue (14%) and loss of taste or smell (14%) being the most common. Their findings in a relatively comparable cohort are thus similar to what we observed in our study. In contrast, an international online survey conducted by Davis et al. among SARS-CoV-2 infected individuals also found a very high symptom prevalence of 65% at 6 months after diagnosis.[10] However, their analysis was restricted to individuals experiencing symptoms for more than 28 days. Another study by Sudre et al. found a prevalence of persistent symptoms lasting longer than 12 weeks in only 2.3% of their participant population, based on an evaluation of data from the Covid Symptoms Study App.[11] Overall, differences in study populations and

outcome measurement are likely to strongly affect the findings of studies on post-COVID-19 syndrome. However, despite the current challenges in making comparisons, a high prevalence of fatigue, dyspnoea or exercise intolerance, and psychological symptoms are consistently noted across studies.[5,6,9–11]

A few studies so far have described the utilisation of healthcare services after COVID-19, in particular hospitalisation.[7,8,31–33] At two months, 9% to 20% of patients admitted for COVID-19 were found to require rehospitalisation, with a higher risk in individuals with comorbidities and older age.[7,8,31–33] The observed rehospitalisation rate of about 10% in our study is broadly consistent with these estimates. Chopra et al. further reported that 78% of participants hospitalised for COVID-19 had seen a primary care physician after hospital discharge.[8] However, the proportion of COVID-19 related primary care consultations was not reported. In our study, 63% of hospitalised participants reported to have had a general practitioner visit after hospital discharge. Again, differences in study populations likely affect the comparability across studies.

Implications for Healthcare Resource Planning

The management and care of individuals with post-COVID-19 syndrome is likely to become a substantial burden for the healthcare systems worldwide. In Switzerland, more than half a million individuals have been diagnosed with COVID-19,[34] and around 1.5 are estimated to have been infected according to current seroprevalence studies.[35] Based on our estimates of the proportion of infected individuals that suffer from longer-term complications, a relevant number of individuals may have to be expected to need some degree of support or healthcare services. In our study, we were able to provide more detail to the possible healthcare utilisation incurring due to COVID-19. We found that more than a third of infected individuals require an average of two further primary care consultations related to protracted symptoms or complications. Interestingly, we also observed that despite an increased likelihood of seeking care in those who have not returned to their normal health status, approximately one third of these participants did not report any contact with their general practitioner since their acute illness. This indicates that there may be a relevant need among previously infected individuals for additional services specialised in caring for people with post-COVID-19 syndrome. Thus, our study provides important evidence for understanding the burden of longer-term complications of COVID-19 on healthcare systems and for planning public health resources and tailored services accordingly.

Strengths and Limitations

The main strength of our study is its population-based approach, which provides a unique opportunity for the evaluation of post-COVID-19 syndrome across the spectrum of disease severity. By relying on official records of PCR-confirmed infections within the Department of Health of the Canton of Zurich for recruitment, we were able to reach individuals diagnosed with infection from the whole population, strengthening the validity of our results. However, our study also has several limitations.

First, most participants included in this analysis were diagnosed with COVID-19 during the first pandemic wave in Switzerland. The limited capacity of SARS-CoV-2 testing at that time may have

selected for a population with a higher risk of experiencing severe disease. However, we observed largely comparable results in sensitivity analyses stratified by time periods of limited and increased testing. Similarly, sensitivity analyses stratified by time periods with different levels of awareness of post-COVID-19 syndrome did not show a relevant difference in people reporting symptoms or not having recovered, indicating that the increased awareness did not result in markedly higher rates of health issues reported by participants (Supplementary Material, Table S2).

Second, self-selection bias may have occurred if individuals who are more concerned with their health were more likely to join our study. Compared to the individuals that did not participate in our study, we observed a higher proportion of individuals aged 40-64 years (48% versus 41%) and a lower proportion of individuals aged 65 years or older (15% versus 21%) in our sample. Furthermore, 24% of nonparticipants were hospitalised for COVID-19 compared to 19% of participants in our study. The distribution of sex and symptomatic COVID-19 were similar among participants and nonparticipants (Supplementary Material, Table S3).

A third limitation is the lack of a baseline (pre-COVID) assessment of participants' health and symptoms, in particular those relating to mental health. Thus, it is impossible to distinguish the effects of COVID-19 from pre-existing conditions. Interpretation of results relating to the impact of COVID-19 on depression and anxiety is further limited by the psychological burden that lockdown measures and the pandemic may have on individuals in general.[36,37] While we tried to compare our results to data from the general population, directly comparable data was not available for most outcomes.

Fourth, we did not evaluate the use of specialised medical (e.g., psychological/psychiatric care) or diagnostic services in our assessment and thus the true extent of healthcare service utilisation may be underestimated. Relating to this, the unavailability of clearly structured post-COVID-19 care programs in Switzerland at the time of enrolment may have led to an underestimation of the healthcare demand in a situation where such programs are available.

And last, our questions regarding the presence of new and ongoing symptoms were not specifically conceived to evaluate the prevalence of post-COVID-19 syndrome. Yet, most of the symptom complexes that have emerged in the literature strongly overlap with what we assessed in the study. Due to the additional exploration of free text responses related to experienced symptoms, as well as the use of standardised questionnaires for the assessment of fatigue, dyspnoea, depression, anxiety and HRQoL, we believe that the key features of post-COVID-19 syndrome are adequately captured in our study. Further studies based on a more targeted in-depth assessment of health outcomes and symptom complexes will be necessary to fully capture the spectrum of post-COVID-19 syndrome.

Conclusion

In our population-based cohort study, we found a considerable proportion of individuals infected with SARS-CoV-2 experience longer-term consequences. We show that individuals suffering from

post-COVID-19 syndrome have a relevant demand for healthcare services after their infection, which has important implications for the planning of healthcare resources. A wide range of services and patient-centred, integrative approaches will be required to support the recovery of these individuals. It is thus critical that the early planning and resource allocation for the care of those suffering from post-COVID-19 syndrome are integrated within response strategies alongside public health measures to mitigate the pandemic.

Summary box

What is already known on this topic

- A wide range of persistent physical and mental health symptoms and complications have been described in individuals recovering from COVID-19 up to six months after infection.
- Most studies relied on distinct subpopulations in their assessments, in particular hospitalised patients, which may limit the generalizability of their findings to the whole spectrum of COVID-19 in the population.
- Data on the utilisation of healthcare services in individuals recovering from COVID-19 is lacking.

What this study adds

- In this population-based cohort study, 26% of individuals had not fully recovered within six to eight months of SARS-CoV-2 infection. 55% of study participants suffered from fatigue, 25% from dyspnoea and 26% had symptoms of depression.
- 40% of participants had at least one further contact with the healthcare system related to COVID-19 after initial illness, with 36% reporting to have had at least one general practitioner visit, and 10% being rehospitalised due to COVID-19 or its complications.
- Given the previous course of the pandemic with millions infected worldwide, our findings underline the need for the timely planning of healthcare resources and services tailored to the needs of individuals suffering from post-COVID-19 syndrome.

Footnotes

Contributors: DM, TB, HEA, JSF and MAP conceived and planned the Zurich SARS-CoV-2 Cohort study. DM, TB and MAP coordinated the Zurich SARS-CoV-2 Cohort study. TB, DM, AA, and MAP designed this study. HEA implemented and coordinated the recruitment of study participants. TB, DM, and AD contributed to the enrolment of study participants and data collection. TB and DM prepared the analytic datasets and performed the statistical analysis. TB and DM drafted the first manuscript. All authors had access to the data in the study and accept responsibility to submit for publication. All authors critically revised the draft manuscript and read and approved the final manuscript. MAP is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: The Zurich SARS-CoV-2 Cohort study is part of the Corona Immunitas research program, coordinated by the Swiss School of Public Health (SSPH+) and funded through SSPH+ fundraising, including funding by the Swiss Federal Office of Public Health, the Cantons of Switzerland (Basel, Vaud and Zurich), private funders (ethical guidelines for funding stated by SSPH+ were respected) and institutional funds of the participating universities. Additional funding specific to this study was provided by the Cantonal Health Directorate Zurich and the University of Zurich Foundation. Study funders had no role in the study design, data collection, analysis, interpretation, or writing of this report.

Ethical approval: The study was approved by the responsible ethics committee of the Canton of Zurich, Switzerland (Kantonale Ethik-Kommission Zürich; BASEC-Nr. 2020-01739). Informed consent was obtained from all participants.

Data sharing: We are open to sharing de-identified individual participant data that underlie the results reported in this article. Requests can be made to the corresponding author. Data requestors will need to sign a data access agreement.

Transparency statement: The manuscript's guarantor (MAP) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

References

1 World Health Organization (WHO). Coronavirus Disease (COVID-19) Situation Reports: Weekly Epidemiological Update 23 February 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed 25 Feb 2021).

2 Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ* 2020;**370**:m3026. doi:10.1136/bmj.m3026

3 National Institute for Health Research (NIHR). Living with Covid19. 2020. doi:10.3310/themedreview_41169

4 National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020. https://www.nice.org.uk/guidance/ng188 (accessed 19 Jan 2021).

5 Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, *et al.* 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet* 2021;**0**. doi:10.1016/S0140-6736(20)32656-8

6 Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC, Baldon G, Bartolomei G, Battaglia M, Battistini S, Binda V, Borg M, Cantaluppi V, Castello LM, Clivati E, Cisari C, Costanzo M, Croce A, Cuneo D, De Benedittis C, *et al.* Respiratory and Psychophysical

Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. *JAMA Netw Open* 2021;**4**:e2036142. doi:10.1001/jamanetworkopen.2020.36142

7 Donnelly JP, Wang XQ, Iwashyna TJ, Prescott HC. Readmission and Death After Initial Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System. *JAMA* 2021;**325**:304. doi:10.1001/jama.2020.21465

8 Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. *Ann Intern Med* (published online first) 11 Nov 2020. doi:10.7326/M20-5661

9 Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, Chu HY. Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA Netw Open* 2021;**4**:e210830. doi:10.1001/jamanetworkopen.2021.0830

10 Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, Redfield S, Austin JP, Akrami A. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. *medRxiv* 2020;:2020.12.24.20248802. doi:10.1101/2020.12.24.20248802

11 Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, Molteni E, Modat M, Cardoso MJ, May A, Ganesh S, Davies R, Nguyen LH, Drew DA, Astley CM, Joshi AD, *et al.* Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. *medRxiv* 2020;:2020.10.19.20214494. doi:10.1101/2020.10.19.20214494

12 Norton A, Olliaro P, Sigfrid L, Carson G, Paparella G, Hastie C, Kaushic C, Boily-Larouche G, Suett JC, O'Hara M. Long COVID: tackling a multifaceted condition requires a multidisciplinary approach. *The Lancet Infectious Diseases* 2021;**0**. doi:10.1016/S1473-3099(21)00043-8

13 National Health Service (NHS) England. Long COVID patients to get help at more than 60 clinics. https://www.england.nhs.uk/2020/12/long-covid-patients-to-get-help-at-more-than-60-clinics/ (accessed 25 Feb 2021).

14 Center for Disease Control and Prevention (CDC). Late Sequelae of COVID-19. Centers for Disease Control and Prevention. 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/late-sequelae.html (accessed 25 Feb 2021).

15 Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. *Journal of Psychosomatic Research* 2003;**54**:345–52. doi:10.1016/S0022-3999(02)00392-6

16 Mahler DA, Wells CK. Evaluation of Clinical Methods for Rating Dyspnea. *Chest* 1988;**93**:580–6. doi:10.1378/chest.93.3.580

17 Depression Anxiety Stress Scales (DASS). http://www2.psy.unsw.edu.au/dass/ (accessed 25 Feb 2021).

18 Lovibond SH, Lovibond PF, Psychology Foundation of Australia. Manual for the depression anxiety stress scales. Psychology Foundation of Australia, Sydney, N.S.W., 1995.

19 Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;**20**:1727–36. doi:10.1007/s11136-011-9903-x

20 Devlin N, Parkin D, Janssen B. An Introduction to EQ-5D Instruments and Their Applications. In: Devlin N, Parkin D, Janssen B, eds. *Methods for Analysing and Reporting*

EQ-5D Data. Springer International Publishing, Cham, 2020. 1–22. doi:10.1007/978-3-030-47622-9_1

21 Carfì A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* 2020;**324**:603. doi:10.1001/jama.2020.12603

22 Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, Flament T, Ferreira-Maldent N, Bruyère F, Stefic K, Gaudy-Graffin C, Grammatico-Guillon L, Bernard L. Follow-up of adults with noncritical COVID-19 two months after symptom onset. *Clinical Microbiology and Infection* 2020;**0**. doi:10.1016/j.cmi.2020.09.052

23 Garrigues E, Janvier P, Kherabi Y, Bot AL, Hamon A, Gouze H, Doucet L, Berkani S, Oliosi E, Mallart E, Corre F, Zarrouk V, Moyer J-D, Galy A, Honsel V, Fantin B, Nguyen Y. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *Journal of Infection* 2020;**81**:e4–6. doi:10.1016/j.jinf.2020.08.029

24 Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, Houben-Wilke S, Burtin C, Posthuma R, Franssen FME, van Loon N, Hajian B, Spies Y, Vijlbrief H, van 't Hul AJ, Janssen DJA, Spruit MA. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? *ERJ Open Res* (published online first) 11 Sep 2020. doi:10.1183/23120541.00542-2020

25 Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S, Corrado J, Singh R, Collins T, O'Connor RJ, Sivan M. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *Journal of Medical Virology* (published online first) 30 Jul 2020. https://eprints.whiterose.ac.uk/164067/ (accessed 17 Feb 2021).

26 Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, Heightman M, Hillman TE, Jacob J, Jarvis HC, Lipman MCI, Naidu SB, Nair A, Porter JC, Tomlinson GS, Hurst JR. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. *Thorax* (published online first) Nov 2020. doi:10.1136/thoraxjnl-2020-215818

27 Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. *Lancet Psychiatry* 2021;**8**:130–40. doi:10.1016/S2215-0366(20)30462-4

28 Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, O'Connor L, Leavy D, O'Brien K, Dowds J, Sugrue JA, Hopkins D, Martin-Loeches I, Cheallaigh CN, Nadarajan P, McLaughlin AM, Bourke NM, Bergin C, O'Farrelly C, Bannan C, *et al.* Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PLOS ONE* 2020;**15**:e0240784. doi:10.1371/journal.pone.0240784

29 Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. *Eur Respir J* 2020;**56**. doi:10.1183/13993003.03276-2020

30 Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, Dong W. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clinical Microbiology and Infection* 2021;**27**:89–95. doi:10.1016/j.cmi.2020.09.023

31 Bowles KH, McDonald M, Barrón Y, Kennedy E, O'Connor M, Mikkelsen M. Surviving COVID-19 After Hospital Discharge: Symptom, Functional, and Adverse Outcomes of

Home Health Recipients. *Ann Intern Med* (published online first) 24 Nov 2020. doi:10.7326/M20-5206

32 Lavery AM, Preston LE, Ko JY, Chevinsky JR, DeSisto CL, Pennington AF, Kompaniyets L, Datta SD, Click ES, Golden T, Goodman AB, Mac Kenzie WR, Boehmer TK, Gundlapalli AV. Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission — United States, March–August 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:1695–9. doi:10.15585/mmwr.mm6945e2

33 McCarthy CP, Murphy S, Jones-O'Connor M, Olshan DS, Khambhati JR, Rehman S, Cadigan JB, Cui J, Meyerowitz EA, Philippides G, Friedman LS, Kadar AY, Hibbert K, Natarajan P, Massaro AF, Bohula EA, Morrow DA, Woolley AE, Januzzi JL, Wasfy JH. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. *EClinicalMedicine* 2020;**26**. doi:10.1016/j.eclinm.2020.100504

34 Swiss Federal Office of Public Health (FOPH). COVID-19 Switzerland: Coronavirus Dashboard. https://www.covid19.admin.ch/en/overview (accessed 25 Feb 2021).

35 Stringhini S, Zaballa M-E, Perez-Saez J, Pullen N, Mestral C de, Picazio A, Pennacchio F, Wisniak A, Richard A, Baysson H, Loizeau A, Balavoine J-F, Trono D, Pittet D, Posfay-Barbe K, Flahault A, Chappuis F, Kherad O, Vuilleumier N, Kaiser L, *et al.* Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak. *The Lancet Infectious Diseases* 2021;**0**. doi:10.1016/S1473-3099(21)00054-2

36 Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. *Brain, Behavior, and Immunity* 2020;**89**:531–42. doi:10.1016/j.bbi.2020.05.048

37 Quervain D de, Aerni A, Amini E, Bentz D, Coynel D, Freytag V, Gerhards C, Papassotiropoulos A, Schicktanz N, Schlitt T, Zimmer A, Zuber P. The Swiss Corona Stress Study: second pandemic wave, November 2020. 2020. doi:10.31219/osf.io/6cseh

Figures & Tables

Figure 1: Flow chart for the inclusion of SARS-CoV-2 infected individuals from the Canton of Zurich, diagnosed between 27 February 2020 and 05 August 2020.



Figure 2: Venn diagram of the overlap of participants that have not fully recovered or are experiencing fatigue, dyspnoea or depression at six to eight months after SARS-CoV-2 infection.



Table 1: Characteristics of study participants enrolled in the Zurich SARS-CoV-2 Cohort study.

Variable	N=431
Age (years)	
Median (IQR)	47 (33 to 58)
Age group (years)	
18-39	164 (38.1%)
40-64	205 (47.6%)
≥65	62 (14.4%)
Sex	
Female	214 (49.7%)
Male	217 (50.3%)
Time since diagnosis (days)	
Median (IQR)	220 (181 to 232)
Initial symptom severity	
Asymptomatic	46 (10.7%)
Mild to moderate	221 (51.3%)
Severe to very severe	164 (38.1%)
Initial symptom count	
Median (IQR)	6 (3 to 8)
Missing	*1*
Initial symptom duration	
Median (IQR)	10 (6 to 20)
Missing	*8*
Hospitalisation and ICU stay	
Non-hospitalised	350 (81.2%)
Hospitalised without ICU stay	71 (16.5%)
Hospitalised with ICU stay	10 (2.3%)
Intubation during ICU stay (N=10)	7 (70%)
Smoking status	
Non-smoker	245 (57.2%)
Ex-smoker	122 (28.5%)
Smoker	61 (14.3%)
Missing	*3*
Body mass index	
Median (IQR)	24.8 (22.2 to 27.5)
Missing	*8*
Comorbidities	
No comorbidity	283 (65.7%)
At least one comorbidity	147 (34.1%)

Missing	*1*
Education	
None or mandatory school	20 (4.7%)
Vocational training or specialised baccalaureate	186 (43.5%)
Higher technical school or college	106 (24.8%)
University	116 (27.1%)
Missing	*3*
Employment	
Employed	321 (75.4%)
Student	14 (3.3%)
Retired	62 (14.6%)
Unemployed or other	29 (6.8%)
Missing	*5*
Income (CHF)	
<6'000	133 (32.8%)
6'000 - 12'000	156 (38.4%)
>12'000	117 (28.8%)
Missing	*25*

Legend: CHF = Swiss Francs, ICU = Intensive Care Unit, IQR = Interquartile Range.

Table 2: Relative health status, fatigue, dyspnoea, mental health, and health-related quality of life in study participants at six to eight months after SARS-CoV-2 infection.

Variable	Age group			Sex		Hospitalisation		
	18-39 years, N=164	**40-64 years**, N=205	**≥65 years**, N=62	**Female**, N=214	**Male**, N=217	**Non-hospitalised**, N=350	**Hospitalised**, N=81	**Overall**, N=431
Recovery								
Recovered to normal health status	133 (81.1%)	140 (68.3%)	47 (75.8%)	148 (69.2%)	172 (79.3%)	268 (76.6%)	52 (64.2%)	320 (74.2%)
Not recovered to normal health status	31 (18.9%)	65 (31.7%)	15 (24.2%)	66 (30.8%)	45 (20.7%)	82 (23.4%)	29 (35.8%)	111 (25.8%)
Self-reported symptoms								
No new or ongoing symptoms	120 (73.2%)	151 (73.7%)	54 (87.1%)	151 (70.6%)	174 (80.2%)	263 (75.1%)	62 (76.5%)	325 (75.4%)
Any new or ongoing symptoms	44 (26.8%)	54 (26.3%)	8 (12.9%)	63 (29.4%)	43 (19.8%)	87 (24.9%)	19 (23.5%)	106 (24.6%)
Recovery and symptoms								
Recovered and symptom-free	105 (64.0%)	116 (56.6%)	44 (71.0%)	114 (53.3%)	151 (69.6%)	221 (63.1%)	44 (54.3%)	265 (61.5%)
Not recovered or experiencing symptoms	59 (36.0%)	89 (43.4%)	18 (29.0%)	100 (46.7%)	66 (30.4%)	129 (36.9%)	37 (45.7%)	166 (38.5%)
Fatigue (measured by FAS)								
No fatigue	59 (36.0%)	100 (49.0%)	34 (58.6%)	86 (40.8%)	107 (49.8%)	154 (44.1%)	39 (50.6%)	193 (45.3%)
Fatigue	105 (64.0%)	104 (51.0%)	24 (41.4%)	125 (59.2%)	108 (50.2%)	195 (55.9%)	38 (49.4%)	233 (54.7%)
Missing	*0*	*1*	*4*	*3*	*2*	*1*	*4*	*5*
Dyspnoea (measured by mMRC scale)								
mMRC grade 0	126 (82.4%)	139 (74.3%)	34 (61.8%)	139 (70.9%)	160 (80.4%)	259 (81.4%)	40 (51.9%)	299 (75.7%)
mMRC grade 1	25 (16.3%)	39 (20.9%)	17 (30.9%)	48 (24.5%)	33 (16.6%)	53 (16.7%)	28 (36.4%)	81 (20.5%)
mMRC grade ≥2	2 (1.3%)	9 (4.8%)	4 (7.3%)	9 (4.6%)	6 (3.0%)	6 (1.9%)	9 (11.7%)	15 (3.8%)
Missing	*11*	*18*	*7*	*18*	*18*	*32*	*4*	*36*
Depression (measured by DASS-21)								
No depression	123 (75.0%)	151 (74.0%)	43 (71.7%)	149 (70.6%)	168 (77.4%)	263 (75.4%)	54 (68.4%)	317 (74.1%)
Mild to moderate depression	33 (20.1%)	39 (19.1%)	13 (21.7%)	50 (23.7%)	35 (16.1%)	68 (19.5%)	17 (21.5%)	85 (19.9%)
Severe to very severe depression	8 (4.9%)	14 (6.9%)	4 (6.7%)	12 (5.7%)	14 (6.5%)	18 (5.2%)	8 (10.1%)	26 (6.1%)
Missing	*0*	*1*	*2*	*3*	*0*	*1*	*2*	*3*
Anxiety (measured by DASS-21)								
No anxiety	114 (69.5%)	136 (67.3%)	41 (68.3%)	125 (59.5%)	166 (76.9%)	246 (70.7%)	45 (57.7%)	291 (68.3%)
Mild to moderate anxiety	38 (23.2%)	47 (23.3%)	18 (30.0%)	64 (30.5%)	39 (18.1%)	82 (23.6%)	21 (26.9%)	103 (24.2%)
Severe to very severe anxiety	12 (7.3%)	19 (9.4%)	1 (1.7%)	21 (10.0%)	11 (5.1%)	20 (5.7%)	12 (15.4%)	32 (7.5%)
Missing	*0*	*3*	*2*	*4*	*1*	*2*	*3*	*5*

Stress (measured by DASS-21)								
No stress	134 (82.2%)	169 (82.8%)	54 (93.1%)	169 (80.1%)	188 (87.9%)	293 (84.2%)	64 (83.1%)	357 (84.0%)
Mild to moderate stress	21 (12.9%)	26 (12.7%)	4 (6.9%)	33 (15.6%)	18 (8.4%)	43 (12.4%)	8 (10.4%)	51 (12.0%)
Severe to very severe stress	8 (4.9%)	9 (4.4%)	0 (0.0%)	9 (4.3%)	8 (3.7%)	12 (3.4%)	5 (6.5%)	17 (4.0%)
Missing	*1*	*1*	*4*	*3*	*3*	*2*	*4*	*6*
EQ-5D mobility								
No mobility problems	156 (95.1%)	180 (87.8%)	45 (75.0%)	188 (88.3%)	193 (89.4%)	324 (92.8%)	57 (71.2%)	381 (88.8%)
Mobility problems	8 (4.9%)	25 (12.2%)	15 (25.0%)	25 (11.7%)	23 (10.6%)	25 (7.2%)	23 (28.7%)	48 (11.2%)
Missing	*0*	*0*	*2*	*1*	*1*	*1*	*1*	*2*
EQ-5D self care								
No problems with self-care	164 (100.0%)	203 (99.0%)	61 (100.0%)	212 (99.5%)	216 (99.5%)	348 (99.4%)	80 (100.0%)	428 (99.5%)
Problems with self-care	0 (0.0%)	2 (1.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	2 (0.6%)	0 (0.0%)	2 (0.5%)
Missing	*0*	*0*	*1*	*1*	*0*	*0*	*1*	*1*
EQ-5D usual activities								
No problems during usual activities	146 (89.0%)	184 (89.8%)	55 (90.2%)	184 (86.4%)	201 (92.6%)	322 (92.0%)	63 (78.8%)	385 (89.5%)
Problems during usual activities	18 (11.0%)	21 (10.2%)	6 (9.8%)	29 (13.6%)	16 (7.4%)	28 (8.0%)	17 (21.2%)	45 (10.5%)
Missing	*0*	*0*	*1*	*1*	*0*	*0*	*1*	*1*
EQ-5D pain & discomfort								
No pain or discomfort present	124 (75.6%)	124 (61.1%)	29 (47.5%)	132 (62.3%)	145 (67.1%)	241 (69.3%)	36 (45.0%)	277 (64.7%)
Pain or discomfort present	40 (24.4%)	79 (38.9%)	32 (52.5%)	80 (37.7%)	71 (32.9%)	107 (30.7%)	44 (55.0%)	151 (35.3%)
Missing	*0*	*2*	*1*	*2*	*1*	*2*	*1*	*3*
EQ-5D anxiety & depression								
No anxiety or depression present	107 (65.2%)	144 (70.2%)	46 (75.4%)	131 (61.5%)	166 (76.5%)	241 (68.9%)	56 (70.0%)	297 (69.1%)
Anxiety or depression present	57 (34.8%)	61 (29.8%)	15 (24.6%)	82 (38.5%)	51 (23.5%)	109 (31.1%)	24 (30.0%)	133 (30.9%)
Missing	*0*	*0*	*1*	*1*	*0*	*0*	*1*	*1*
EQ-5D-5L index score								
Median (IQR)	1.00 (0.86 to 1.00)	0.89 (0.85 to 1.00)	0.89 (0.82 to 1.00)	0.89 (0.82 to 1.00)	1.00 (0.87 to 1.00)	1.00 (0.86 to 1.00)	0.88 (0.82 to 1.00)	0.89 (0.85 to 1.00)
Range	0.41 to 1.00	0.07 to 1.00	0.47 to 1.00	0.37 to 1.00	0.07 to 1.00	0.07 to 1.00	0.37 to 1.00	0.07 to 1.00
Missing	*0*	*2*	*2*	*2*	*2*	*3*	*1*	*4*
EQ VAS								
Median (IQR)	85 (80 to 90)	85 (77 to 90)	80 (70 to 88)	85 (77 to 90)	85 (79 to 90)	85 (80 to 90)	80 (70 to 89)	85 (77 to 90)
Range	20 to 100	25 to 100	24 to 95	20 to 100	24 to 100	25 to 100	20 to 97	20 to 100
Missing	*2*	*6*	*2*	*6*	*4*	*5*	*5*	*10*

Legend: FAS = Fatigue Assessment Scale, mMRC = modified Medical Research Council, DASS-21 = Depression, Anxiety and Stress Score (21 items), EQ = EuroQol, VAS = Visual Analogue Scale, IQR = Interquartile Range.

Table 3: Healthcare use, complications and socio-economic consequences at six to eight months after SARS-CoV-2 infection.

Variable	Age group			Sex		Hospitalisation		
	18-39 years, N=164	**40-64 years**, N=205	**≥65 years**, N=62	**Female**, N=214	**Male**, N=217	**Non-hospitalised**, N=350	**Hospitalised**, N=81	**Overall**, N=431
GP visit related to COVID-19	33 (20.4%)	85 (42.7%)	32 (53.3%)	80 (38.5%)	70 (32.9%)	100 (29.2%)	50 (63.3%)	150 (35.6%)
Missing	*2*	*6*	*2*	*6*	*4*	*8*	*2*	*10*
Number of GP visits related to COVID-19[1]								
1-2	22 (67%)	63 (75%)	21 (66%)	56 (71%)	50 (71%)	70 (71%)	36 (72%)	106 (71%)
3-5	10 (30%)	18 (21%)	8 (25%)	19 (24%)	17 (24%)	26 (26%)	10 (20%)	36 (24%)
≥6	1 (3%)	3 (4%)	3 (9%)	4 (5%)	3 (4%)	3 (3%)	4 (8%)	7 (5%)
Missing	*0*	*1*	*0*	*1*	*0*	*1*	*0*	*1*
Medical hotline contact related to COVID-19	16 (9.8%)	13 (6.3%)	2 (3.3%)	19 (8.9%)	12 (5.6%)	25 (7.2%)	6 (7.4%)	31 (7.2%)
Missing	*0*	*0*	*1*	*0*	*1*	*1*	*0*	*1*
Number of medical hotline contacts related to COVID-19[1]								
1-2	14 (88%)	7 (70%)	2 (100%)	15 (88%)	8 (73%)	18 (78%)	5 (100%)	23 (82%)
3-5	2 (12%)	3 (30%)	0 (0%)	2 (12%)	3 (27%)	5 (22%)	0 (0%)	5 (18%)
≥6	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Missing	*0*	*3*	*0*	*2*	*1*	*2*	*1*	*3*
Rehospitalisations related to COVID-19 (N=81)	1 (10%)	3 (7%)	4 (14%)	4 (11%)	4 (10%)	-	8 (10%)	8 (10%)
Number of rehospitalisations related to COVID-19[1]								
1	0 (0%)	3 (100%)	4 (100%)	3 (75%)	4 (100%)	-	7 (88%)	7 (88%)
2-3	1 (100%)	0 (0%)	0 (0%)	1 (25%)	0 (0%)	-	1 (12%)	1 (12%)
GP visit or rehospitalisation related to COVID-19	34 (21.0%)	85 (42.7%)	33 (55.0%)	82 (39.4%)	70 (32.9%)	100 (29.2%)	52 (65.8%)	152 (36.1%)
Missing	*2*	*6*	*2*	*6*	*4*	*8*	*2*	*10*
Healthcare contact related to COVID-19	45 (27.8%)	92 (46.2%)	33 (55.0%)	94 (45.2%)	76 (35.7%)	116 (33.9%)	54 (68.4%)	170 (40.4%)
Missing	*2*	*6*	*2*	*6*	*4*	*8*	*2*	*10*
New medical diagnoses	12 (7.3%)	47 (22.9%)	18 (29.0%)	36 (16.8%)	41 (18.9%)	43 (12.3%)	34 (42.0%)	77 (17.9%)
Type of new medical diagnosis[2]								
COVID-19 related complication (medically evaluated)	2 (17%)	17 (36%)	8 (44%)	12 (33%)	15 (37%)	12 (28%)	15 (44%)	27 (35%)
COVID-19 related complication (self-evaluated)	3 (25%)	6 (13%)	2 (11%)	6 (17%)	5 (12%)	7 (16%)	4 (12%)	11 (14%)
Non COVID-19 related diagnosis or unclear	7 (58%)	24 (51%)	8 (44%)	18 (50%)	21 (51%)	24 (56%)	15 (44%)	39 (51%)

Change in scope of work due to infection or isolation	89 (54.3%)	91 (44.8%)	6 (10.3%)	80 (38.5%)	106 (48.8%)	160 (46.4%)	26 (32.5%)	186 (43.8%)
Missing	*0*	*2*	*4*	*6*	*0*	*5*	*1*	*6*
Reduced income due to infection or isolation	18 (11.0%)	30 (14.7%)	1 (1.7%)	26 (12.3%)	23 (10.7%)	38 (10.9%)	11 (14.3%)	49 (11.5%)
Not sure	3 (1.8%)	7 (3.4%)	2 (3.4%)	8 (3.8%)	4 (1.9%)	8 (2.3%)	4 (5.2%)	12 (2.8%)
Missing	*0*	*1*	*4*	*3*	*2*	*1*	*4*	*5*

Legend: GP = General Practitioner, FAS = Fatigue Assessment Scale, mMRC = modified Medical Research Council, DASS-21 = Depression, Anxiety and Stress Score (21 items), EQ = EuroQol, VAS = Visual Analogue Scale, IQR = Interquartile Range. [1] percentage within each category of healthcare contact (general practitioner visit, medical hotline call, rehospitalisaion), [2] percentage among all medical diagnoses.